Clinical Accelerator, a full-service, medical device focused contract research organization, is pleased to announce a new partnership with CryoTherapeutics – an early-stage European medical device company which has developed a novel cryoenergy therapy for the treatment of inflamed atherosclerotic plaque, a major cause of myocardial infraction.
Currently there is no approved interventional treatment for this indication, but CryoTherapeutics hopes to change that with their therapy which will target areas of the coronary artery where there is inflammatory disease. The system consists of a console delivering a cryogen to the tip of a catheter which then delivers cryotherapy at below zero temperatures to the specific site in the coronary artery. The procedure is conducted with the assistance of invasive of non-invasive imaging to ensure precise placement
CryoTherapeutics’s feasibility study will be managed by Clinical Accelerator and we are thrilled to be a part of this project. We are looking forward to using our expertise in clinical trial management of FIH and early feasibility studies to result in a successful study.
About Clinical Accelerator
Clinical Accelerator is an independent clinical trial management organisation operating principally in Central and Eastern Europe. The organisation offers a broad range of clinical trial services together with dedicated patient enrolment support to worldwide clients in the pharmaceutical, biotechnological and medical device industries. Clinical Accelerator’s model of operation is designed to achieve significant cost savings for its clients and to guarantee compact timelines for patient enrolment with a firm focus on the quality of clinical trial data.